+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Age-related Macular Degeneration Market by Route Of Administration, Treatment, Drug Class, Type, End User, Distribution Channel, Stage - Global Forecast to 2030- Product Image
Age-related Macular Degeneration Market by Route Of Administration, Treatment, Drug Class, Type, End User, Distribution Channel, Stage - Global Forecast to 2030- Product Image
Sale

Age-related Macular Degeneration Market by Route Of Administration, Treatment, Drug Class, Type, End User, Distribution Channel, Stage - Global Forecast to 2030

  • PDF Icon

    Report

  • 192 Pages
  • May 2025
  • Region: Global
  • 360iResearch™
  • ID: 5665786
UP TO OFF until Dec 31st 2025
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Age-related Macular Degeneration Market grew from USD 11.10 billion in 2024 to USD 11.82 billion in 2025. It is expected to continue growing at a CAGR of 6.75%, reaching USD 16.43 billion by 2030.

Setting the Stage for Age-related Macular Degeneration Insights

Age-related macular degeneration (AMD) stands as one of the foremost causes of vision impairment among older adults, commanding the attention of clinicians, researchers, and industry stakeholders alike. As demographic trends push global populations toward increased longevity, the prevalence of AMD continues to rise, placing renewed emphasis on both therapeutic innovation and healthcare infrastructure readiness. This executive summary distills critical insights from the latest research, capturing market dynamics, emerging clinical paradigms, and strategic considerations that will shape the future of AMD management.

Our analysis synthesizes diverse data streams-from regulatory filings and clinical trial outcomes to manufacturer strategies and patient care pathways-offering a 360-degree view of the AMD landscape. By beginning with foundational context on disease burden and evolving treatment paradigms, this introduction frames the report’s subsequent sections, ensuring that decision-makers can navigate the complexities of product development, reimbursement challenges, and competitive positioning with confidence.

Emerging Forces Redefining the AMD Therapeutic Arena

Over the past decade, the AMD arena has experienced transformative shifts driven by breakthroughs in molecular targeting, sustained-release drug delivery, and precision diagnostics. The transition from mono-agent intravitreal injections to next-generation implantable devices has introduced longer dosing intervals and improved patient adherence, reducing clinic visit frequency and mitigating treatment burden. Simultaneously, advancements in gene therapy and RNA-based modalities are progressing through early-stage clinical trials, promising potentially curative interventions that go beyond existing pharmacological management.

Regulatory frameworks have adapted to these innovations, with expedited pathways for breakthrough therapies and conditional approvals for adaptive trial designs. Real-world evidence generated through integrated electronic health records increasingly informs payor negotiations and value-based contracting models. Collectively, these forces are redefining the competitive landscape, encouraging strategic collaborations among biotech pioneers, established pharmaceutical players, and technology providers focused on digital biomarkers and remote patient monitoring.

Assessing the Ripple Effects of New US Tariff Measures

In early 2025, newly implemented tariffs targeting imported ophthalmic devices and specialized pharmaceuticals have begun reshaping supply chain economics. Manufacturers reliant on overseas production of implant delivery systems and precision instrumentation have encountered elevated input costs, necessitating price adjustments or the onshoring of critical manufacturing processes. These measures have catalyzed a reexamination of global sourcing strategies, prompting some companies to diversify supplier bases across Asia-Pacific and Latin America to mitigate exposure to U.S. trade policy fluctuations.

From a market access perspective, increased costs have placed pressure on hospital budgets and outpatient clinic reimbursement schedules. Healthcare providers are evaluating bundled therapy offerings and value-based agreements to offset incremental expenses. Simultaneously, domestic producers of intravitreal injection kits have experienced a competitive uptick, leveraging localized supply chains and quicker turnaround times. As these dynamics evolve, industry leaders must remain agile, anticipating further adjustments to tariff schedules and aligning commercial strategies with shifting regulatory landscapes.

Unpacking Market Segments Driving Strategic Decisions

Analyzing the market through a segmentation lens reveals nuanced drivers steering investment and innovation. Treatments delivered via implantable devices and intravitreal injections each offer distinct value propositions: implants promise extended drug release reducing visit frequency, while injections maintain flexibility for dose adjustments and combination regimens. Within treatment modalities, non-pharmacological approaches such as laser therapy and photodynamic therapy continue to serve niche patient subsets, yet pharmacological options dominate with anti-VEGF molecules and corticosteroid formulations. Leading anti-VEGF agents like aflibercept, bevacizumab, brolucizumab, and ranibizumab compete on efficacy profiles and dosing intervals, while corticosteroids such as dexamethasone and triamcinolone offer adjunctive benefits in refractory cases.

Examining drug classes highlights the ascendancy of anti-VEGF therapies, which represent the backbone of wet AMD management, whereas corticosteroids address inflammatory components and are particularly relevant in combination protocols. Dry AMD, characterized by geographic atrophy, remains an unmet need, fueling research into complement inhibitors and neuroprotective agents. End-user segmentation identifies clinics, hospitals, and specialty ophthalmic centers as primary administration sites, each demanding tailored service models and reimbursement frameworks. Distribution channels span hospital pharmacies, online platforms, and retail outlets, underscoring the importance of omnichannel strategies to ensure consistent product availability. Finally, disease stage stratification into early, intermediate, and late phases informs treatment algorithms and guides patient enrollment criteria in ongoing clinical studies, highlighting opportunities for early detection and intervention initiatives.

Regional Dynamics Shaping Global AMD Opportunities

Regional market trajectories are shaped by heterogeneous factors spanning demographics, healthcare funding models, and regulatory pathways. In the Americas, robust reimbursement frameworks and high per-capita healthcare spending facilitate the adoption of premium-priced therapies, while emerging tele-ophthalmology platforms enhance screening capabilities in underserved areas. Europe, the Middle East, and Africa display diverse landscapes: Western European nations lead in technology uptake supported by value-based agreements, whereas certain EMEA regions face infrastructure constraints that temper growth, underscoring the need for cost-effective diagnostic and treatment solutions.

Asia-Pacific represents a dual narrative of opportunity and complexity. Rapid population aging in countries such as Japan, South Korea, and China drives demand for advanced AMD therapies, while government initiatives to expand universal health coverage fuel market access. However, fragmented regulatory requirements and variable local manufacturing capacity necessitate region-specific launch strategies. Across all regions, the interplay between public sector procurement, private insurance coverage, and out-of-pocket spending shapes the timing and scale of product rollouts, compelling manufacturers to adopt flexible pricing and commercialization models.

Competitive Landscape and Leading Therapeutic Innovators

The competitive landscape for AMD therapeutics is anchored by a core group of innovators alongside agile biotechs advancing first-in-class approaches. Major players have fortified their portfolios through licensing agreements, strategic alliances, and targeted acquisitions to bolster pipeline depth. Leading anti-VEGF developers continue to refine molecule potency and delivery mechanisms, while newer entrants explore gene editing and cell-based therapies to address underlying disease pathology.

In parallel, medical device manufacturers and contract development organizations vie to provide state-of-the-art delivery platforms, including biodegradable implants and micro-pump systems. Companies at the forefront of digital health are integrating artificial intelligence for automated fundus imaging analysis, offering real-time disease progression models that inform personalized treatment schedules. As these incumbents and challengers jockey for position, partnerships between pharmaceutical and technology firms are becoming increasingly commonplace, reflecting the interdisciplinary nature of next-generation AMD solutions.

Strategic Imperatives for Maximizing AMD Market Success

Industry leaders aiming to capitalize on these market dynamics should prioritize the development of sustained-release formulations that reduce treatment burden and differentiate in a crowded anti-VEGF space. Investing in platforms that enable personalized dosing regimens based on real-world disease progression data can enhance patient retention and payor support. Companies must also anticipate policy shifts by building flexible supply chains capable of adapting to evolving tariff structures and regional regulatory variations.

Cultivating partnerships with digital health providers to integrate remote monitoring and predictive analytics can streamline clinical workflows and support value-based contracting. Furthermore, expanding access programs in emerging markets through tiered pricing and local manufacturing collaborations will drive volume growth while reinforcing corporate social responsibility commitments. By aligning R&D priorities with unmet needs in geographic atrophy and early AMD detection, organizations can unlock new market segments and establish leadership in innovative therapeutic classes.

Robust Framework Underpinning Our Analytical Approach

This analysis is grounded in a rigorous framework combining primary research interviews with key opinion leaders, clinical investigators, and payor representatives, alongside secondary data drawn from regulatory filings, scientific literature, and industry databases. Market dynamics were triangulated through cross-verification of competing data sets, while segmentation insights emerged from detailed pipeline assessments and product usage patterns.

Synthesis of AMD Landscape and Strategic Pathways Ahead

The age-related macular degeneration landscape is at an inflection point, shaped by transformative therapeutic advances, evolving policy environments, and shifting patient care paradigms. Stakeholders who embrace data-driven decision making, cultivate cross-sector partnerships, and remain attuned to regional nuances will be best positioned to capture emerging opportunities. As the market continues to evolve, strategic agility and a focus on unmet needs-particularly within dry AMD and sustained-release delivery systems-will determine long-term success.

Market Segmentation & Coverage

This research report categorizes to forecast the revenues and analyze trends in each of the following sub-segmentations:
  • Route Of Administration
    • Implant
    • Intravitreal Injection
  • Treatment
    • Non-Pharmacological
      • Laser Therapy
      • Photodynamic Therapy
    • Pharmacological
      • Anti-Vegf
        • Aflibercept
        • Bevacizumab
        • Brolucizumab
        • Ranibizumab
      • Corticosteroid
        • Dexamethasone
        • Triamcinolone
  • Drug Class
    • Anti-Vegf
      • Aflibercept
      • Bevacizumab
      • Brolucizumab
      • Ranibizumab
    • Corticosteroid
      • Dexamethasone
      • Triamcinolone
  • Type
    • Dry
      • Geographic Atrophy
    • Wet
  • End User
    • Clinics
    • Hospitals
    • Specialty Ophthalmic Centers
  • Distribution Channel
    • Hospital Pharmacy
    • Online Pharmacy
    • Retail Pharmacy
  • Stage
    • Early
    • Intermediate
    • Late
This research report categorizes to forecast the revenues and analyze trends in each of the following sub-regions:
  • Americas
    • United States
      • California
      • Texas
      • New York
      • Florida
      • Illinois
      • Pennsylvania
      • Ohio
    • Canada
    • Mexico
    • Brazil
    • Argentina
  • Europe, Middle East & Africa
    • United Kingdom
    • Germany
    • France
    • Russia
    • Italy
    • Spain
    • United Arab Emirates
    • Saudi Arabia
    • South Africa
    • Denmark
    • Netherlands
    • Qatar
    • Finland
    • Sweden
    • Nigeria
    • Egypt
    • Turkey
    • Israel
    • Norway
    • Poland
    • Switzerland
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • Indonesia
    • Thailand
    • Philippines
    • Malaysia
    • Singapore
    • Vietnam
    • Taiwan
This research report categorizes to delves into recent significant developments and analyze trends in each of the following companies:
  • Regeneron Pharmaceuticals, Inc.
  • Bayer AG
  • Novartis AG
  • Roche Holding AG
  • Alcon Inc.
  • Carl Zeiss Meditec AG
  • Topcon Corporation
  • Nidek Co., Ltd.
  • Heidelberg Engineering GmbH
  • Optos plc

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Age-related Macular Degeneration Market, by Route Of Administration
8.1. Introduction
8.2. Implant
8.3. Intravitreal Injection
9. Age-related Macular Degeneration Market, by Treatment
9.1. Introduction
9.2. Non-Pharmacological
9.2.1. Laser Therapy
9.2.2. Photodynamic Therapy
9.3. Pharmacological
9.3.1. Anti-Vegf
9.3.1.1. Aflibercept
9.3.1.2. Bevacizumab
9.3.1.3. Brolucizumab
9.3.1.4. Ranibizumab
9.3.2. Corticosteroid
9.3.2.1. Dexamethasone
9.3.2.2. Triamcinolone
10. Age-related Macular Degeneration Market, by Drug Class
10.1. Introduction
10.2. Anti-Vegf
10.2.1. Aflibercept
10.2.2. Bevacizumab
10.2.3. Brolucizumab
10.2.4. Ranibizumab
10.3. Corticosteroid
10.3.1. Dexamethasone
10.3.2. Triamcinolone
11. Age-related Macular Degeneration Market, by Type
11.1. Introduction
11.2. Dry
11.2.1. Geographic Atrophy
11.3. Wet
12. Age-related Macular Degeneration Market, by End User
12.1. Introduction
12.2. Clinics
12.3. Hospitals
12.4. Specialty Ophthalmic Centers
13. Age-related Macular Degeneration Market, by Distribution Channel
13.1. Introduction
13.2. Hospital Pharmacy
13.3. Online Pharmacy
13.4. Retail Pharmacy
14. Age-related Macular Degeneration Market, by Stage
14.1. Introduction
14.2. Early
14.3. Intermediate
14.4. Late
15. Americas Age-related Macular Degeneration Market
15.1. Introduction
15.2. United States
15.3. Canada
15.4. Mexico
15.5. Brazil
15.6. Argentina
16. Europe, Middle East & Africa Age-related Macular Degeneration Market
16.1. Introduction
16.2. United Kingdom
16.3. Germany
16.4. France
16.5. Russia
16.6. Italy
16.7. Spain
16.8. United Arab Emirates
16.9. Saudi Arabia
16.10. South Africa
16.11. Denmark
16.12. Netherlands
16.13. Qatar
16.14. Finland
16.15. Sweden
16.16. Nigeria
16.17. Egypt
16.18. Turkey
16.19. Israel
16.20. Norway
16.21. Poland
16.22. Switzerland
17. Asia-Pacific Age-related Macular Degeneration Market
17.1. Introduction
17.2. China
17.3. India
17.4. Japan
17.5. Australia
17.6. South Korea
17.7. Indonesia
17.8. Thailand
17.9. Philippines
17.10. Malaysia
17.11. Singapore
17.12. Vietnam
17.13. Taiwan
18. Competitive Landscape
18.1. Market Share Analysis, 2024
18.2. FPNV Positioning Matrix, 2024
18.3. Competitive Analysis
18.3.1. Regeneron Pharmaceuticals, Inc.
18.3.2. Bayer AG
18.3.3. Novartis AG
18.3.4. Roche Holding AG
18.3.5. Alcon Inc.
18.3.6. Carl Zeiss Meditec AG
18.3.7. Topcon Corporation
18.3.8. Nidek Co., Ltd.
18.3.9. Heidelberg Engineering GmbH
18.3.10. Optos plc
19. ResearchAI
20. ResearchStatistics
21. ResearchContacts
22. ResearchArticles
23. Appendix
List of Figures
FIGURE 1. AGE-RELATED MACULAR DEGENERATION MARKET MULTI-CURRENCY
FIGURE 2. AGE-RELATED MACULAR DEGENERATION MARKET MULTI-LANGUAGE
FIGURE 3. AGE-RELATED MACULAR DEGENERATION MARKET RESEARCH PROCESS
FIGURE 4. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 5. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2030 (%)
FIGURE 8. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TREATMENT, 2024 VS 2030 (%)
FIGURE 10. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TREATMENT, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DRUG CLASS, 2024 VS 2030 (%)
FIGURE 12. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DRUG CLASS, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TYPE, 2024 VS 2030 (%)
FIGURE 14. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 16. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 18. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY STAGE, 2024 VS 2030 (%)
FIGURE 20. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY STAGE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. AMERICAS AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. AMERICAS AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. UNITED STATES AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 24. UNITED STATES AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. EUROPE, MIDDLE EAST & AFRICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 26. EUROPE, MIDDLE EAST & AFRICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 27. ASIA-PACIFIC AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 28. ASIA-PACIFIC AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 29. AGE-RELATED MACULAR DEGENERATION MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 30. AGE-RELATED MACULAR DEGENERATION MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. AGE-RELATED MACULAR DEGENERATION MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY IMPLANT, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY INTRAVITREAL INJECTION, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY NON-PHARMACOLOGICAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY LASER THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY PHOTODYNAMIC THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY NON-PHARMACOLOGICAL, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY PHARMACOLOGICAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY ANTI-VEGF, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY AFLIBERCEPT, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY BEVACIZUMAB, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY BROLUCIZUMAB, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY RANIBIZUMAB, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY ANTI-VEGF, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY CORTICOSTEROID, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DEXAMETHASONE, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TRIAMCINOLONE, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY CORTICOSTEROID, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY PHARMACOLOGICAL, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY ANTI-VEGF, BY REGION, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY AFLIBERCEPT, BY REGION, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY BEVACIZUMAB, BY REGION, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY BROLUCIZUMAB, BY REGION, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY RANIBIZUMAB, BY REGION, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY ANTI-VEGF, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY CORTICOSTEROID, BY REGION, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DEXAMETHASONE, BY REGION, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TRIAMCINOLONE, BY REGION, 2018-2030 (USD MILLION)
TABLE 36. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY CORTICOSTEROID, 2018-2030 (USD MILLION)
TABLE 37. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 38. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DRY, BY REGION, 2018-2030 (USD MILLION)
TABLE 39. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY GEOGRAPHIC ATROPHY, BY REGION, 2018-2030 (USD MILLION)
TABLE 40. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DRY, 2018-2030 (USD MILLION)
TABLE 41. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY WET, BY REGION, 2018-2030 (USD MILLION)
TABLE 42. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 43. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 44. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 45. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY SPECIALTY OPHTHALMIC CENTERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 46. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 47. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
TABLE 48. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2030 (USD MILLION)
TABLE 49. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
TABLE 50. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY STAGE, 2018-2030 (USD MILLION)
TABLE 51. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY EARLY, BY REGION, 2018-2030 (USD MILLION)
TABLE 52. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY INTERMEDIATE, BY REGION, 2018-2030 (USD MILLION)
TABLE 53. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY LATE, BY REGION, 2018-2030 (USD MILLION)
TABLE 54. AMERICAS AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 55. AMERICAS AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 56. AMERICAS AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY NON-PHARMACOLOGICAL, 2018-2030 (USD MILLION)
TABLE 57. AMERICAS AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY PHARMACOLOGICAL, 2018-2030 (USD MILLION)
TABLE 58. AMERICAS AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY ANTI-VEGF, 2018-2030 (USD MILLION)
TABLE 59. AMERICAS AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY CORTICOSTEROID, 2018-2030 (USD MILLION)
TABLE 60. AMERICAS AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 61. AMERICAS AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY ANTI-VEGF, 2018-2030 (USD MILLION)
TABLE 62. AMERICAS AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY CORTICOSTEROID, 2018-2030 (USD MILLION)
TABLE 63. AMERICAS AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 64. AMERICAS AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DRY, 2018-2030 (USD MILLION)
TABLE 65. AMERICAS AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 66. AMERICAS AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 67. AMERICAS AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY STAGE, 2018-2030 (USD MILLION)
TABLE 68. AMERICAS AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 69. UNITED STATES AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 70. UNITED STATES AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 71. UNITED STATES AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY NON-PHARMACOLOGICAL, 2018-2030 (USD MILLION)
TABLE 72. UNITED STATES AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY PHARMACOLOGICAL, 2018-2030 (USD MILLION)
TABLE 73. UNITED STATES AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY ANTI-VEGF, 2018-2030 (USD MILLION)
TABLE 74. UNITED STATES AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY CORTICOSTEROID, 2018-2030 (USD MILLION)
TABLE 75. UNITED STATES AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 76. UNITED STATES AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY ANTI-VEGF, 2018-2030 (USD MILLION)
TABLE 77. UNITED STATES AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY CORTICOSTEROID, 2018-2030 (USD MILLION)
TABLE 78. UNITED STATES AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 79. UNITED STATES AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DRY, 2018-2030 (USD MILLION)
TABLE 80. UNITED STATES AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 81. UNITED STATES AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 82. UNITED STATES AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY STAGE, 2018-2030 (USD MILLION)
TABLE 83. UNITED STATES AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 84. CANADA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 85. CANADA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 86. CANADA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY NON-PHARMACOLOGICAL, 2018-2030 (USD MILLION)
TABLE 87. CANADA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY PHARMACOLOGICAL, 2018-2030 (USD MILLION)
TABLE 88. CANADA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY ANTI-VEGF, 2018-2030 (USD MILLION)
TABLE 89. CANADA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY CORTICOSTEROID, 2018-2030 (USD MILLION)
TABLE 90. CANADA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 91. CANADA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY ANTI-VEGF, 2018-2030 (USD MILLION)
TABLE 92. CANADA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY CORTICOSTEROID, 2018-2030 (USD MILLION)
TABLE 93. CANADA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 94. CANADA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DRY, 2018-2030 (USD MILLION)
TABLE 95. CANADA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 96. CANADA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 97. CANADA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY STAGE, 2018-2030 (USD MILLION)
TABLE 98. MEXICO AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 99. MEXICO AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 100. MEXICO AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY NON-PHARMACOLOGICAL, 2018-2030 (USD MILLION)
TABLE 101. MEXICO AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY PHARMACOLOGICAL, 2018-2030 (USD MILLION)
TABLE 102. MEXICO AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY ANTI-VEGF, 2018-2030 (USD MILLION)
TABLE 103. MEXICO AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY CORTICOSTEROID, 2018-2030 (USD MILLION)
TABLE 104. MEXICO AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 105. MEXICO AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY ANTI-VEGF, 2018-2030 (USD MILLION)
TABLE 106. MEXICO AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY CORTICOSTEROID, 2018-2030 (USD MILLION)
TABLE 107. MEXICO AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 108. MEXICO AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DRY, 2018-2030 (USD MILLION)
TABLE 109. MEXICO AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 110. MEXICO AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 111. MEXICO AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY STAGE, 2018-2030 (USD MILLION)
TABLE 112. BRAZIL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 113. BRAZIL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 114. BRAZIL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY NON-PHARMACOLOGICAL, 2018-2030 (USD MILLION)
TABLE 115. BRAZIL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY PHARMACOLOGICAL, 2018-2030 (USD MILLION)
TABLE 116. BRAZIL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY ANTI-VEGF, 2018-2030 (USD MILLION)
TABLE 117. BRAZIL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY CORTICOSTEROID, 2018-2030 (USD MILLION)
TABLE 118. BRAZIL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 119. BRAZIL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY ANTI-VEGF, 2018-2030 (USD MILLION)
TABLE 120. BRAZIL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY CORTICOSTEROID, 2018-2030 (USD MILLION)
TABLE 121. BRAZIL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 122. BRAZIL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DRY, 2018-2030 (USD MILLION)
TABLE 123. BRAZIL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 124. BRAZIL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 125. BRAZIL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY STAGE, 2018-2030 (USD MILLION)
TABLE 126. ARGENTINA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 127. ARGENTINA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 128. ARGENTINA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY NON-PHARMACOLOGICAL, 2018-2030 (USD MILLION)
TABLE 129. ARGENTINA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY PHARMACOLOGICAL, 2018-2030 (USD MILLION)
TABLE 130. ARGENTINA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY ANTI-VEGF, 2018-2030 (USD MILLION)
TABLE 131. ARGENTINA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY CORTICOSTEROID, 2018-2030 (USD MILLION)
TABLE 132. ARGENTINA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 133. ARGENTINA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY ANTI-VEGF, 2018-2030 (USD MILLION)
TABLE 134. ARGENTINA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY CORTICOSTEROID, 2018-2030 (USD MILLION)
TABLE 135. ARGENTINA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 136. ARGENTINA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DRY, 2018-2030 (USD MILLION)
TABLE 137. ARGENTINA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 138. ARGENTINA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 139. ARGENTINA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY STAGE, 2018-2030 (USD MILLION)
TABLE 140. EUROPE, MIDDLE EAST & AFRICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 141. EUROPE, MIDDLE EAST & AFRICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 142. EUROPE, MIDDLE EAST & AFRICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY NON-PHARMACOLOGICAL, 2018-2030 (USD MILLION)
TABLE 143. EUROPE, MIDDLE EAST & AFRICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY PHARMACOLOGICAL, 2018-2030 (USD MILLION)
TABLE 144. EUROPE, MIDDLE EAST & AFRICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY ANTI-VEGF, 2018-2030 (USD MILLION)
TABLE 145. EUROPE, MIDDLE EAST & AFRICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY CORTICOSTEROID, 2018-2030 (USD MILLION)
TABLE 146. EUROPE, MIDDLE EAST & AFRICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 147. EUROPE, MIDDLE EAST & AFRICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY ANTI-VEGF, 2018-2030 (USD MILLION)
TABLE 148. EUROPE, MIDDLE EAST & AFRICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY CORTICOSTEROID, 2018-2030 (USD MILLION)
TABLE 149. EUROPE, MIDDLE EAST & AFRICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 150. EUROPE, MIDDLE EAST & AFRICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DRY, 2018-2030 (USD MILLION)
TABLE 151. EUROPE, MIDDLE EAST & AFRICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 152. EUROPE, MIDDLE EAST & AFRICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 153. EUROPE, MIDDLE EAST & AFRICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY STAGE, 2018-2030 (USD MILLION)
TABLE 154. EUROPE, MIDDLE EAST & AFRICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 155. UNITED KINGDOM AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 156. UNITED KINGDOM AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 157. UNITED KINGDOM AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY NON-PHARMACOLOGICAL, 2018-2030 (USD MILLION)
TABLE 158. UNITED KINGDOM AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY PHARMACOLOGICAL, 2018-2030 (USD MILLION)
TABLE 159. UNITED KINGDOM AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY ANTI-VEGF, 2018-2030 (USD MILLION)
TABLE 160. UNITED KINGDOM AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY CORTICOSTEROID, 2018-2030 (USD MILLION)
TABLE 161. UNITED KINGDOM AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 162. UNITED KINGDOM AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY ANTI-VEGF, 2018-2030 (USD MILLION)
TABLE 163. UNITED KINGDOM AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY CORTICOSTEROID, 2018-2030 (USD MILLION)
TABLE 164. UNITED KINGDOM AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 165. UNITED KINGDOM AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DRY, 2018-2030 (USD MILLION)
TABLE 166. UNITED KINGDOM AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 167. UNITED KINGDOM AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 168. UNITED KINGDOM AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY STAGE, 2018-2030 (USD MILLION)
TABLE 169. GERMANY AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 170. GERMANY AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 171. GERMANY AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY NON-PHARMACOLOGICAL, 2018-2030 (USD MILLION)
TABLE 172. GERMANY AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY PHARMACOLOGICAL, 2018-2030 (USD MILLION)
TABLE 173. GERMANY AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY ANTI-VEGF, 2018-2030 (USD MILLION)
TABLE 174. GERMANY AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY CORTICOSTEROID, 2018-2030 (USD MILLION)
TABLE 175. GERMANY AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 176. GERMANY AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY ANTI-VEGF, 2018-2030 (USD MILLION)
TABLE 177. GERMANY AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY CORTICOSTEROID, 2018-2030 (USD MILLION)
TABLE 178. GERMANY AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 179. GERMANY AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DRY, 2018-2030 (USD MILLION)
TABLE 180. GERMANY AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 181. GERMANY AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 182. GERMANY AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY STAGE, 2018-2030 (USD MILLION)
TABLE 183. FRANCE AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 184. FRANCE AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 185. FRANCE AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY NON-PHARMACOLOGICAL, 2018-2030 (USD MILLION)
TABLE 186. FRANCE AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY PHARMACOLOGICAL, 2018-2030 (USD MILLION)
TABLE 187. FRANCE AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY ANTI-VEGF, 2018-2030 (USD MILLION)
TABLE 188. FRANCE AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY CORTICOSTEROID, 2018-2030 (USD MILLION)
TABLE 189. FRANCE AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 190. FRANCE AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY ANTI-VEGF, 2018-2030 (USD MILLION)
TABLE 191. FRANCE AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY CORTICOSTEROID, 2018-2030 (USD MILLION)
TABLE 192. FRANCE AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 193. FRANCE AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DRY, 2018-2030 (USD MILLION)
TABLE 194. FRANCE AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 195. FRANCE AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 196. FRANCE AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY STAGE, 2018-2030 (USD MILLION)
TABLE 197. RUSSIA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 198. RUSSIA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 199. RUSSIA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY NON-PHARMACOLOGICAL, 2018-2030 (USD MILLION)
TABLE 200. RUSSIA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY PHARMACOLOGICAL, 2018-2030 (USD MILLION)
TABLE 201. RUSSIA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY ANTI-VEGF, 2018-2030 (USD MILLION)
TABLE 202. RUSSIA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY CORTICOSTEROID, 2018-2030 (USD MILLION)
TABLE 203. RUSSIA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 204. RUSSIA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY ANTI-VEGF, 2018-2030 (USD MILLION)
TABLE 205. RUSSIA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY CORTICOSTEROID, 2018-2030 (USD MILLION)
TABLE 206. RUSSIA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 207. RUSSIA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DRY, 2018-2030 (USD MILLION)
TABLE 208. RUSSIA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 209. RUSSIA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 210. RUSSIA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY STAGE, 2018-2030 (USD MILLION)
TABLE 211. ITALY AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 212. ITALY AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 213. ITALY AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY NON-PHARMACOLOGICAL, 2018-2030 (USD MILLION)
TABLE 214. ITALY AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY PHARMACOLOGICAL, 2018-2030 (USD MILLION)
TABLE 215. ITALY AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY ANTI-VEGF, 2018-2030 (USD MILLION)
TABLE 216. ITALY AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY CORTICOSTEROID, 2018-2030 (USD MILLION)
TABLE 217. ITALY AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 218. ITALY AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY ANTI-VEGF, 2018-2030 (USD MILLION)
TABLE 219. ITALY AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY CORTICOSTEROID, 2018-2030 (USD MILLION)
TABLE 220. ITALY AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 221. ITALY AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DRY, 2018-2030 (USD MILLION)
TABLE 222. ITALY AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 223. ITALY AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 224. ITALY AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY STAGE, 2018-2030 (USD MILLION)
TABLE 225. SPAIN AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 226. SPAIN AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 227. SPAIN AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY NON-PHARMACOLOGICAL, 2018-2030 (USD MILLION)
TABLE 228. SPAIN AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY PHARMACOLOGICAL, 2018-2030 (USD MILLION)
TABLE 229. SPAIN AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY ANTI-VEGF, 2018-2030 (USD MILLION)
TABLE 230. SPAIN AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY CORTICOSTEROID, 2018-2030 (USD MILLION)
TABLE 231. SPAIN AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 232. SPAIN AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY ANTI-VEGF, 2018-2030 (USD MILLION)
TABLE 233. SPAIN AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY CORTICOSTEROID, 2018-2030 (USD MILLION)
TABLE 234. SPAIN AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 235. SPAIN AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DRY, 2018-2030 (USD MILLION)
TABLE 236. SPAIN AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 237. SPAIN AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 238. SPAIN AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY STAGE, 2018-2030 (USD MILLION)
TABLE 239. UNITED ARAB EMIRATES AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 240. UNITED ARAB EMIRATES AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 241. UNITED ARAB EMIRATES AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY NON-PHARMACOLOGICAL, 2018-2030 (USD MILLION)
TABLE 242. UNITED ARAB EMIRATES AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY PHARMACOLOGICAL, 2018-2030 (USD MILLION)
TABLE 243. UNITED ARAB EMIRATES AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY ANTI-VEGF, 2018-2030 (USD MILLION)
TABLE 244. UNITED ARAB EMIRATES AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY CORTICOSTEROID, 2018-2030 (USD MILLION)
TABLE 245. UNITED ARAB EMIRATES AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 246. UNITED ARAB EMIRATES AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY ANTI-VEGF, 2018-2030 (USD MILLION)
TABLE 247. UNITED ARAB EMIRATES AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY CORTICOSTEROID, 2018-2030 (USD MILLION)
TABLE 248. UNITED ARAB EMIRATES AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 249. UNITED ARAB EMIRATES AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DRY, 2018-2030 (USD MILLION)
TABLE 250. UNITED ARAB EMIRATES AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 251. UNITED ARAB EMIRATES AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 252. UNITED ARAB EMIRATES AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY STAGE, 2018-2030 (USD MILLION)
TABLE 253. SAUDI ARABIA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 254. SAUDI ARABIA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 255. SAUDI ARABIA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY NON-PHARMACOLOGICAL, 2018-2030 (USD MILLION)
TABLE 256. SAUDI ARABIA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY PHARMACOLOGICAL, 2018-2030 (USD MILLION)
TABLE 257. SAUDI ARABIA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY ANTI-VEGF, 2018-2030 (USD MILLION)
TABLE 258. SAUDI ARABIA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY CORTICOSTEROID, 2018-2030 (USD MILLION)
TABLE 259. SAUDI ARABIA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 260. SAUDI ARABIA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY ANTI-VEGF, 2018-2030 (USD MILLION)
TABLE 261. SAUDI ARABIA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY CORTICOSTEROID, 2018-2030 (USD MILLION)
TABLE 262. SAUDI ARABIA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 263. SAUDI ARABIA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DRY, 2018-2030 (USD MILLION)
TABLE 264. SAUDI ARABIA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 265. SAUDI ARABIA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 266. SAUDI ARABIA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY STAGE, 2018-2030 (USD MILLION)
TABLE 267. SOUTH AFRICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 268. SOUTH AFRICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 269. SOUTH AFRICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY NON-PHARMACOLOGICAL, 2018-2030 (USD MILLION)
TABLE 270. SOUTH AFRICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY PHARMACOLOGICAL, 2018-2030 (USD MILLION)
TABLE 271. SOUTH AFRICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY ANTI-VEGF, 2018-2030 (USD MILLION)
TABLE 272. SOUTH AFRICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY CORTICOSTEROID, 2018-2030 (USD MILLION)
TABLE 273. SOUTH AFRICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 274. SOUTH AFRICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY ANTI-VEGF, 2018-2030 (USD MILLION)
TABLE 275. SOUTH AFRICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY CORTICOSTEROID, 2018-2030 (USD MILLION)
TABLE 276. SOUTH AFRICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 277. SOUTH AFRICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DRY, 2018-2030 (USD MILLION)
TABLE 278. SOUTH AFRICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 279. SOUTH AFRICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 280. SOUTH AFRICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY STAGE, 2018-2030 (USD MILLION)
TABLE 281. DENMARK AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 282. DENMARK AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 283. DENMARK AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY NON-PHARMACOLOGICAL, 2018-2030 (USD MILLION)
TABLE 284. DENMARK AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY PHARMACOLOGICAL, 2018-2030 (USD MILLION)
TABLE 285. DENMARK AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY ANTI-VEGF, 2018-2030 (USD MILLION)
TABLE 286. DENMARK AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY CORTICOSTEROID, 2018-2030 (USD MILLION)
TABLE 287. DENMARK AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 288. DENMARK AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY ANTI-VEGF, 2018-2030 (USD MILLION)
TABLE 289. DENMARK AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY CORTICOSTEROID, 2018-2030 (USD MILLION)
TABLE 290. DENMARK AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 291. DENMARK AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DRY, 2018-2030 (USD MILLION)
TABLE 292. DENMARK AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 293. DENMARK AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 294. DENMARK AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY STAGE, 2018-2030 (USD MILLION)
TABLE 295. NETHERLANDS AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 296. NETHERLANDS AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 297. NETHERLANDS AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY NON-PHARMACOLOGICAL, 2018-2030 (USD MILLION)
TABLE 298. NETHERLANDS AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY PHARMACOLOGICAL, 2018-2030 (USD MILLION)
TABLE 299. NETHERLANDS AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY ANTI-VEGF, 2018-2030 (USD MILLION)
TABLE 300. NETHERLANDS AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY CORTICOSTEROID, 2018-2030 (USD MILLION)
TABLE 301. NETHERLANDS AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 302. NETHERLANDS AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY ANTI-VEG

Companies Mentioned

The companies profiled in this Age-related Macular Degeneration market report include:
  • Regeneron Pharmaceuticals, Inc.
  • Bayer AG
  • Novartis AG
  • Roche Holding AG
  • Alcon Inc.
  • Carl Zeiss Meditec AG
  • Topcon Corporation
  • Nidek Co., Ltd.
  • Heidelberg Engineering GmbH
  • Optos plc

Methodology

Loading
LOADING...

Table Information

Report AttributeDetails
No. of Pages192
PublishedMay 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 11.82 Billion
Forecasted Market Value ( USD ) by 2030 $ 16.43 Billion
Compound Annual Growth Rate6.7%
Regions CoveredGlobal
No. of Companies Mentioned11

Related Topics

Related Reports

Age-Related Macular Degeneration Market Size, Share and Trends Analysis Report by Product (Eylea, Lucentis), Disease (Wet AMD, Dry AMD), Distribution Channel, and Region 2024-2030 - Product Image

Age-Related Macular Degeneration Market Size, Share and Trends Analysis Report by Product (Eylea, Lucentis), Disease (Wet AMD, Dry AMD), Distribution Channel, and Region 2024-2030

  • Report
  • 100 Pages
  • Global
From
Wet Macular Degeneration Market - Product Image

Wet Macular Degeneration Market

  • Report
  • 250 Pages
  • Global
From
Juvenile Macular Degeneration Market - Product Image

Juvenile Macular Degeneration Market

  • Report
  • 250 Pages
  • Global
From
Age-Related Macular Degeneration - Global Strategic Business Report - Product Image

Age-Related Macular Degeneration - Global Strategic Business Report

  • Report
  • 367 Pages
  • Global
From
Wet Age-Related Macular Degeneration (Wet AMD) - Market Insight, Epidemiology and Market Forecast - 2034 - Product Image

Wet Age-Related Macular Degeneration (Wet AMD) - Market Insight, Epidemiology and Market Forecast - 2034

  • Report
  • 200 Pages
  • Global
From

About the Market

Age-related Macular Degeneration (AMD) is a degenerative eye condition that affects the macula, the part of the eye responsible for central vision. It is the leading cause of vision loss in people over the age of 50. AMD is a major concern for the optical industry, as it can lead to severe vision impairment and blindness. Optical companies are developing treatments and technologies to help diagnose and manage AMD. These include optical coherence tomography (OCT) imaging, which can detect early signs of AMD, and anti-VEGF drugs, which can slow the progression of the disease. Additionally, companies are developing new lenses and other optical devices to help improve vision in those with AMD. Companies in the AMD market include Novartis, Regeneron, Allergan, Genentech, and Roche. Show Less Read more

Copyright © 2002-2025 Research and Markets. All Rights Reserved.